Peer-influenced content. Sources you trust. No registration required. This is HCN.
Women’s Healthcare
A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.
Family Nursing July 28th 2026
News Medical
Prenatal fish oil supplementation was associated with small differences in cerebral blood flow and oxygen metabolism at age 10. Cognitive and psychopathology outcomes showed no significant association.
Family Medicine/General Practice July 27th 2026
Psych Congress Network
A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.
Psychiatry July 14th 2026
Healthline
Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.
Internal Medicine July 14th 2026
MDLinx
Primary care physicians increasingly inherit adult ADHD stimulant prescriptions amid specialist shortages and medication supply disruptions. Expert guidance highlights diagnostic verification, monitoring, and risk-assessment considerations without establishing a single standardized approach.
Family Medicine/General Practice July 14th 2026
Psychiatry Advisor
Youth with ADHD and comorbid ASD showed distinct medication patterns and greater psychiatric burden in a large EHR cohort. The observational findings did not establish causal treatment effects.
Pediatric Neurology July 14th 2026